Asklepios BioPharmaceutical, Inc.
https://www.askbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asklepios BioPharmaceutical, Inc.
The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
Gene Therapy Safety Issues Reflect Pushing Of The Scientific Envelope – FDA’s Marks
Recent adverse events are ‘speed bumps’ that need to be worked around, biologics center head Peter Marks says; Morgan Stanley’s Peter Hwang asserts high-profile safety issues have added to unpredictability of gene therapy development, dampening investor enthusiasm for the field.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis